🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

676 results for “Solid” Clear

  1. C5951001- A Phase 1 Study of PF-08046876 in Participants with Advanced Solid Tumors.

    Pfizer Australia Pty Ltd

    advanced solid tumors

    phase 1 other active

    1 trial

  2. C6081001: A Phase 1 Study of PF-07985045 in Participants with Advanced Solid Tumors

    Pfizer Australia Pty Ltd

    KRAS mutated advanced solid tumors

    phase 1 other active

    1 trial

  3. CEP-37250/KHK2804

    Teva Pharma GmbH

    Solid Tumour

    phase 1 small molecule completed

    1 trial

  4. CEP-37440

    Teva Pharma GmbH

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  5. CEP-9722

    Teva Pharma GmbH

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  6. CEP-9722

    Teva Pharma GmbH

    Solid Tumors or Mantle Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  7. CFT1946

    C4 Therapeutics

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  8. CGT4255

    Cogent Biosciences

    Advanced Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  9. CHR-2797 (tosedostat)

    United Therapeutics Europe Ltd

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  10. CHS-006 (anti-TIGIT)

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  11. CHS-1000

    Coherus Oncology

    Advanced or Metastatic Solid Tumors

    phase 1 mab active

    1 trial

  12. CHS-114

    Coherus Oncology

    Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

  13. CHS-114

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  14. CHS-388

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  15. CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer

    The George Institute

    Patients with recurrent and/or metastatic solid cancer.

    phase 1 other active

    1 trial

  16. CLN-617

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  17. CLN-619

    Cullinan Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  18. CLR 131

    Cellectar Biosciences

    Pediatric Solid Tumor

    phase 1 small molecule active

    1 trial

  19. CT053PTSA

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  20. CTX-471

    Compass Therapeutics

    Locally Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  21. CX-188

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  22. CX-2051

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  23. CX-801

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  24. CX-904

    CytomX Therapeutics

    Solid Tumors

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources